1. Acknowledgement to Referees

   Acknowledgement to Referees 09 November 2013 Pages: 1029 - 1031

2. Random-Effects Linear Modeling and Sample Size Tables for Two Special Crossover Designs of Average Bioequivalence Studies: The Four-Period, Two-Sequence, Two-Formulation and Six-Period, Three-Sequence, Three-Formulation Designs

   • Francisco J. Diaz
   • Michel J. Berg
   • Michael Privitera

   Leading Article 02 October 2013 Pages: 1033 - 1043

3. Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders

   • Philip N. Patsalos

   Review Article 22 June 2013 Pages: 1045 - 1061

4. Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents

   • Sameer Doshi
   • Wojciech Krzyzanski
   • Juan José Pérez-Ruixo

   Review Article 03 August 2013 Pages: 1063 - 1083

   

5. Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling

   • Zoe E. Barter
   • Geoffrey T. Tucker
   • Karen Rowland-Yeo

   Original Research Article 02 July 2013 Pages: 1085 - 1100

   

6. Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

   • Sven Wind
   • Marion Schmid
   • Peter Stopfer

   Original Research Article 28 June 2013 Pages: 1101 - 1109

   

7. Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin

   • Carlos Pérez-Ruixo
   • Belén Valenzuela
   • Juan José Pérez-Ruixo

   Original Research Article 05 July 2013 Pages: 1111 - 1125

   

8. Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates

   • Wei Zhao
   • Valérie Biran
   • Evelyne Jacqz-Aigrain

   Short Communication 12 September 2013 Pages: 1127 - 1134